|
Market Closed -
Nasdaq
16:00:00 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 4.630 USD | -3.74% |
|
-8.32% | -47.51% |
| 08-24 | Vanda Pharmaceuticals' Skin Disease Drug Gets EU Orphan Drug Designation | MT |
| 08-10 | B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating | MT |
| Market Cap | 280M 249M 232M 212M 399M 26.91B 403M 2.81B 1.09B 13.76B 1.05B 1.03B 44.15B | P/E 2026 * |
-1.53x | P/E 2027 * | -4.83x |
|---|---|---|---|---|---|
| Enterprise Value | 175M 155M 145M 132M 249M 16.8B 251M 1.75B 680M 8.59B 656M 642M 27.57B | EV / Sales 2026 * |
0.7x | EV / Sales 2027 * | 0.45x |
| Free-Float |
90.67% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VNDA | Delayed | |
CBOE
| VNDA | Real-time | |
|
Tradegate
| VM4 | Real-time | |
|
Deutsche Boerse AG
| VM4 | Delayed | |
|
Börse Stuttgart
| VM4 | Delayed | |
|
Berne S.E.
| VM4 | End-of-day quote | |
|
Boerse Muenchen
| VM4 | Real-time |
Last Transcript: Vanda Pharmaceuticals Inc.
| 1 day | -3.74% | ||
| 1 week | -8.32% | ||
| Current month | -5.70% | ||
| 1 month | -13.30% | ||
| 3 months | -25.44% | ||
| 6 months | -33.86% | ||
| Current year | -47.51% |
| 1 week | 4.56 |  | 5.19 |
| 1 month | 4.56 | | 5.44 |
| Current year | 4.45 | | 9.94 |
| 1 year | 4.27 | | 9.94 |
| 3 years | 3.3 | | 9.94 |
| 5 years | 3.3 | | 21.44 |
| 10 years | 3.3 | | 33.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 2003-04-30 | |
Kevin Moran
DFI | Director of Finance/CFO | 42 | 2020-03-14 |
Scott Howell
HRO | Human Resources Officer | 51 | 2019-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 66 | 2021-05-31 | |
Richard Dugan
BRD | Director/Board Member | 84 | 2005-11-30 |
Phaedra Chrousos
BRD | Director/Board Member | 46 | 2019-04-23 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/4/26 | Free | Director | 41,600 | 0.0692% | ||
| 6/4/26 | Free | Director | 41,600 | 0.0692% | ||
| 6/4/26 | Free | Director | 41,600 | 0.0692% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.74% | -8.32% | -14.73% | +12.11% | 280M | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +20.19% | +81.44% | 57.39B | |
| +0.89% | -0.63% | +2.17% | +36.19% | 47.64B | |
| +0.36% | +0.81% | +342.39% | +742.40% | 44.29B | |
| -0.96% | -4.50% | +24.96% | +35.38% | 42.5B | |
| -0.20% | -0.77% | +4.13% | +105.50% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.33% | +22.72% | 28.53B | |
| +0.05% | -1.64% | -8.14% | -11.37% | 24.34B | |
| Average | -0.58% | -1.36% | +45.90% | +116.90% | 39.08B | |
| Weighted average by Cap. | +0.12% | -0.85% | +56.91% | +138.17% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 249M 221M 206M 188M 355M 23.93B 358M 2.5B 968M 12.23B 934M 914M 39.25B | 337M 300M 280M 255M 481M 32.42B 485M 3.38B 1.31B 16.57B 1.27B 1.24B 53.19B |
| Net income | -182M -162M -151M -138M -260M -17.5B -262M -1.83B -708M -8.95B -684M -669M -28.72B | -69.69M -61.92M -57.79M -52.67M -99.34M -6.7B -100M -699M -271M -3.42B -262M -256M -10.99B |
| Net Debt | -105M -93.44M -87.21M -79.49M -150M -10.11B -151M -1.06B -409M -5.17B -395M -386M -16.59B | -127M -113M -105M -95.85M -181M -12.19B -182M -1.27B -493M -6.23B -476M -466M -20B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-02 | US$4.630 | -3.74% | 1,448,962 |
| 26-10-01 | US$4.810 | -2.04% | 1,351,733 |
| 26-09-30 | US$4.910 | -2.39% | 3,077,088 |
| 26-09-29 | US$5.030 | -2.71% | 2,669,411 |
| 26-09-28 | US$5.170 | +2.38% | 813,075 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VNDA Stock
Select your edition
All financial news and data tailored to specific country editions
